Scope Fluidics S.A.

Warsaw Stock Exchange SCP.WA

Scope Fluidics S.A. Return on Equity (ROE) for the year ending December 31, 2023: -23.21%

Scope Fluidics S.A. Return on Equity (ROE) is -23.21% for the year ending December 31, 2023, a -124.27% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Scope Fluidics S.A. Return on Equity (ROE) for the year ending December 31, 2022 was 95.65%, a 375.37% change year over year.
Scope Fluidics S.A. Return on Equity (ROE) for the year ending December 31, 2021 was -34.73%, a -54.13% change year over year.
Scope Fluidics S.A. Return on Equity (ROE) for the year ending December 31, 2020 was -22.54%, a 27.87% change year over year.
Scope Fluidics S.A. Return on Equity (ROE) for the year ending December 31, 2019 was -31.24%, a 1.78% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Warsaw Stock Exchange: SCP.WA

Scope Fluidics S.A.

CEO	Mr. Piotr Garstecki
IPO Date	Aug. 1, 2017
Location	Poland
Headquarters	9th floor
Employees	40
Sector	Healthcare
Industries Biotechnology Medical Instruments

Description

Scope Fluidics S.A., a biotechnology company, engages in the designing and developing projects based on microfluidic technologies in medical diagnostics and healthcare. It offers BacterOMIC, an antibiotic susceptibility testing. The company was founded in 2010 and is based in Warsaw, Poland.

Key trends

Past 5 years